Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Oligometastatic Disease Clinical Trial

Official title: Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation

Status Terminated

Clinical Trial Summary

This study will evaluate the feasibility of radiosurgery for all metastatic sites in patients presenting with oligometastatic disease, defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems.

Clinical Trial Description

Death from metastatic cancer is a common cause of death, accounting for 80-90% of cancer deaths. The classic thought process is that metastatic disease represents the continuum such that known metastatic disease is an inevitable harbinger for subsequent metastatic disease. However, it has been reported that a subset of patients with limited volume metastatic disease may have a better prognosis if given aggressive therapy. This group of patients has become known as "oligometastatic". These patients are potentially curable with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) (collectively referred to as stereotactic body radiotherapy or SBRT) to the metastatic disease sites in combination with standard curative therapy to the primary site. Patients in this study receive SRS/SBRT to all sites of oligometastatic disease. ;

Related Conditions & MeSH terms

• Oligometastatic Disease

• NCT number: NCT01345539
• Study type: Interventional
• Source: University of Pittsburgh
• Status: Terminated
• Phase: Phase 2
• Start date: June 7, 2013
• Completion date: October 20, 2022